Patient-reported outcomes from the PRIMA trial comparing niraparib treatment versus placebo for patients with newly diagnosed advanced ovarian, primary peritoneal, or fallopian tube cancer with a complete or partial response to first-line platinum-based chemotherapy were similar for the niraparib and placebo arms.
Nivolumab versus Gemcitabine or Pegylated Liposomal Doxorubicin for Patients with Platinum-Resistant Ovarian Cancer: The NINJA Trial
A phase 3 study comparing nivolumab to treatment with gemcitabine or pegylated liposomal doxorubicin for patients with platinum-resistant ovarian cancer revealed similar overall survival and response rates between the 2 groups. Nivolumab was better tolerated than gemcitabine/pegylated liposomal doxorubicin, with fewer all-grade and grade 3/4 adverse events.
Individualized Starting Dose of Niraparib to Treat Platinum-Sensitive Recurrent Ovarian Cancer: The NORA Trial
The NORA study evaluated the efficacy and safety of niraparib when administered using an individualized starting dose for patients with platinum-sensitive, recurrent ovarian cancer. Niraparib improved outcomes such as progression-free survival and demonstrated a tolerable safety profile.
Chemotherapy After Progression on Maintenance Olaparib in BRCA-Mutated Platinum-Sensitive Ovarian Cancer
A post-hoc analysis of the SOLO2 trial investigated the efficacy of chemotherapy after progression while on maintenance olaparib versus placebo in patients with platinum-sensitive ovarian cancer and found chemotherapy to be less efficacious in patients who received maintenance olaparib versus placebo.
This network meta-analysis comparing first-line maintenance therapies in advanced ovarian cancer revealed that PARP inhibitors result in better outcomes than antiangiogenic agents. Individual PARP inhibitors vary in efficacy and adverse events across mutation subtypes.
Results from the GEICO1601-ROLANDO Phase 2 Trial Evaluating Combination of Olaparib and PLD in Platinum-Resistant Ovarian Cancer
In patients with platinum-resistant ovarian cancer, 46% treated per protocol with olaparib and pegylated liposomal doxorubicin (PLD) achieved 6-month progression-free survival regardless of BRCA status. Adverse events were less frequent with a reduction of the PLD dose.
Results of 5-Year Follow-Up of Maintenance Olaparib in Patients with Newly Diagnosed, Advanced Ovarian Cancer
The SOLO1 trial studied maintenance olaparib in newly diagnosed patients with advanced BRCA-mutated ovarian cancer. This analysis assesses outcomes 5 years after the last patient enrolled in the trial and represents the longest follow-up for a PARP inhibitor trial in this setting.
Olaparib + Durvalumab and Bevacizumab: Initial Results in Patients with Non-Germline BRCA-Mutated Platinum-Sensitive Relapsed Ovarian Cancer
For patients with non-germline BRCA-mutated platinum-sensitive relapsed ovarian cancer, the triple combination of olaparib, durvalumab, and bevacizumab demonstrated a promising 24-week disease control rate and safety profile while the combination of olaparib plus durvalumab did not meet the prespecified efficacy target.
The VIRO-15 trial of intraperitoneal Olvi-Vec virus infusion followed by intravenous carboplatin-doublet ± bevacizumab in pretreated platinum-resistant/refractory ovarian cancer patients revealed promising response rates and progression-free survival. Safety results were consistent with a previous phase 1b trial of this agent.
Efficacy and Safety of Niraparib in Older Patients with Advanced Ovarian Cancer from PRIMA/ENGOT-OV26/GOG-3012
In patients with advanced ovarian cancer, niraparib resulted in similar efficacy, safety, and quality-of-life outcomes for patients 65 years of age and those ≥65 years of age. An individualized starting dose resulted in fewer grade ≥3 thrombocytopenia events than a fixed starting dose.
Page 2 of 3
Results 11 - 20 of 24
Results 11 - 20 of 24